Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100502 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
A Phase 3 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT01100502 is a Phase 3 study that has completed, run by Seagen. The registered enrollment target is 329 participants.
The verdict
NCT01100502, a Phase 3 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).
Interventions
- DRUG placebo
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2010-04-30 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100502
The ClinicalTrials.gov registry entry for NCT01100502 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01100502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100502 about?
NCT01100502 is a clinical study titled "A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)". This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (A...
What is the current status of trial NCT01100502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2010-04-30. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT01100502?
The interventions under investigation include: placebo (DRUG), brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT01100502?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.